Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CRHBP | P24387 | 2/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747876 | 0.78 | MAOA (0.37) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL9116482 | 0.74 | MAOA (0.37) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL654481 | 0.68 | MAOA (0.35) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL1724509 | 0.67 | MAOA (0.42) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL217973 | 0.67 | — | — | |
| SCHEMBL7178792 | 0.64 | TSHR (0.38) | MAOAMAOBOXTRACHE | |
| SCHEMBL2098459 | 0.64 | OXTR (0.47) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL19859855 | 0.64 | — | — | |
| SCHEMBL17933760 | 0.61 | MAOA (0.46) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL9209 | 0.60 | MAOA (0.41) | MAOAMAOBOXTRABCG2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | claimed |
| EP-0686156-B1 | PYRAZOLITRIAZINES WITH INTERLEUKIN-1 AND TUMOUR NECROSIS FACTOR INHIBITORY ACTIVITY | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-17 | — | — | EP | claimed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | claimed |
| US-5739130-A | TREATING SYSTEMIC LUPUS ERYTHEMATOSIS, MELANOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-14 | — | — | US | claimed |
| US-5583135-A | TREATING SYSTEMIC LUPUS ERYTHEMATOSIS OR MELANOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-10 | — | — | US | claimed |
| WO-1995003298-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-02 | — | — | WO | claimed |
| US-5338743-A | Pancreatitis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-16 | — | — | US | claimed |
| US-5322842-A | Tricyclic benzodiazepine derivates, their preparation, and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-21 | — | — | US | claimed |
| US-5248679-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-28 | — | — | US | claimed |
| US-5217952-A | Analgesics, antihistamine | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-08 | — | — | US | claimed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | claimed |
| US-20240239805-A1 | AZA-YANG CYCLIZATION-BUCHNER AROMATIC RING EXPANSION: COLLECTIVE SYNTHESIS OF CYCLOHEPTATRIENE-CONTAINING AZETIDINE LACTONES | UNIVERSITY OF KANSAS | 2024-07-18 | — | — | US | disclosed |
| EP-4398911-A2 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | Memorial Sloan Kettering Cancer Center (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-115210273-B | Process for controlling the formation of ziegler-natta procatalyst particles and use for olefin polymerization | 布拉斯科美国公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240231224-A9 | HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF | LAM RESEARCH CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-4264597-A | FUNGICIDES | FUJISAWA PHARMACEUTICAL CO., LTD., NO. 3, 4-CHOME, DOSHOMACHI, HIGASHI-KU, OSAKA, JAPAN | 1981-04-28 | — | — | US | disclosed |
| EP-0025199-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-03-18 | — | — | EP | disclosed |
| US-4234724-A | OXADETHIACEPHEMCARBOXYLIC ACIDS | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1980-11-18 | — | — | US | disclosed |
| EP-0017138-A2 | Analogous compounds of cephalosporins, processes for their preparation, and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-10-15 | — | — | EP | disclosed |
| EP-0009548-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239805-A1 | AZA-YANG CYCLIZATION-BUCHNER AROMATIC RING EXPANSION: COLLECTIVE SYNTHESIS OF CYCLOHEPTATRIENE-CONTAINING AZETIDINE LACTONES | AZI2, NISCH, TET2 | MAOA 123/4885MAOB 31/4885OXTR 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.